About this trial
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Patient Profile
For patients with solid tumours or hematologic malignancies who are currently on treatment or in follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Where’s this trial being run?
St James’s Hospital, Tallaght University Hospital, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK-3475-587 |
|---|---|
| Number: | 24-17 |
| Full Title: | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab. |
| Principal Investigator: | Prof. Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Merck Sharp & Dohme LLC |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | 3500 |
|---|---|
| Ireland Recruitment Target: | 25 |